Pharmaceuticals News and Research

RSS

Clinical trials activity of Synexus in Hungary increases 25% in first-half of 2010

Synexus clinical trials activity in Hungary has increased by 25% during the first half of 2010. The company's Dedicated Research Centre has been operating in Hungary since 2006 and has become one of the company's most successful CEE sites. The Budapest-based operation has been involved in excess of 74 trials since being acquired by Synexus, and randomized over 600 patients.

From AES - Accelerated Enrollment Solutions 16 Aug 2010

R-Tech Ueno, Sucampo Pharmaceuticals request arbitration against Takeda Pharmaceutical

R-Tech Ueno supplies Amitiza (TM) Capsules to Takeda pursuant to agreements with Takeda and Sucampo. On March 12, 2010, Sucampo submitted for filing with the International Court of Arbitration, International Chamber of Commerce, a Request for Arbitration against Takeda. In that Request, Sucampo claimed that Takeda has violated the provisions of the October 29, 2004, Collaboration and License Agreement between Sucampo and Takeda and other applicable duties, and that Takeda's violations have injured Sucampo. Sucampo requested all appropriate relief, including termination of the agreements, damages remedy and so on.

16 Aug 2010

Watson to launch ella emergency contraceptive in fourth-quarter 2010

Watson Pharmaceuticals, Inc., today announced that it intends to launch ella® (ulipristal acetate), a novel oral emergency contraceptive, in the fourth quarter of 2010. Watson's announcement follows the approval of ella® by the FDA as safe and effective in preventing unintended pregnancy for up to 120 hours – or five days – post-unprotected intercourse (UPI) or contraceptive failure.

16 Aug 2010

US WorldMeds announces acquisition of Solstice Neurosciences for $35M

US WorldMeds, LLC, a Kentucky-based specialty pharmaceutical company that develops unique products to address unmet medical needs, today announced it has acquired Solstice Neurosciences, Inc. for $35 million. The acquisition expands US WorldMeds' operations, adds to the company's growing portfolio of products and enhances the company's ability to create and deliver high-quality specialty pharmaceutical products to its targeted global markets.

16 Aug 2010

Aeolus Pharmaceuticals second quarter 2010 net loss increases to $0.10 per share

Aeolus Pharmaceuticals, Inc. announced today financial results for the three months ended June 30, 2010. The Company reported a net loss of $4,623,000, or $0.10 per share, compared to a net loss of $426,000, or $0.01 per share, for the three months ended June 30, 2009. The third quarter 2010 results include a non-cash financing and change in valuation charge of $3,856,000. Loss from operations for the three months ended June 30, 2010 were $750,000 compared to $445,000 for the three months ended June 30, 2009.

16 Aug 2010

Inovio Pharmaceuticals 2010 second quarter net loss decreases

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2010.Total revenue was $1.1 million and $2.5 million for the three and six months ended June 30, 2010, compared to $2.5 million and $2.9 million for the three and six months ended June 30, 2009, respectively.

16 Aug 2010

Nymox second-quarter net loss increases to $1.75 million

Nymox Pharmaceutical Corporation announced today its financial results for the second quarter of 2010. Nymox reported a net loss of $1,745,798, or $0.05 per share for the quarter and $3,015,348, or $0.10 per share for the six months ending June 30, 2010, compared to $1,220,152, or $0.04 per share for the quarter and $2,224,411, or $0.07 per share for the six months ending June 30, 2009. Net losses include stock compensation charges for the quarter of $245,245 in 2010 and $248,886 in 2009 and for the six months ending June 30 of $440,465 in 2010 and $558,536 in 2009.

16 Aug 2010

Avenue to Access provides free prescription-size tube of ZITHRANOL-RR to stable plaque psoriasis patients

During the month of August, people with a certain type of psoriasis have the chance to access free medicine through Avenue to Access. The program is designed to help individuals with mild-to-moderate stable plaque psoriasis access to a free prescription-size tube of ZITHRANOL-RR (anthralin, 1.2%) rapid release microcrystalline encapsulated cream.

16 Aug 2010

U.S. officials probing payments by drug and device makers to doctors overseas

The New York Times reports that federal officials are investigating whether a dozen drug and device makers "made illegal payments to doctors and health officials in foreign countries." Although pharmaceutical companies routinely contract with doctors in the United States to be consultants, experts say the situation is more complex overseas because "in much of the rest of the world, doctors are government employees. And even consulting arrangements that would be considered routine in the United States might violate the Foreign Corrupt Practices Act, particularly if the payments are outsize or the arrangements are not disclosed to the governments.

16 Aug 2010

AIBioTech receives new government contract worth $21 million

American International Biotechnology Services (AIBioTech), a division of Bostwick Laboratories, Richmond, VA, today announced that it is one of four contractors awarded a new government contract valued at approximately $21 million. AIBioTech provides integrated research and development sciences and clinical testing services to physicians and life sciences investigators in biotechnology and pharmaceutical companies, academic institutions, and government agencies. The new contract will be funded in phases, with the first AIBioTech phase valued at nearly $3 million. AIBioTech has assembled a consortium of seven leading technology and biotechnology companies who are poised to meet all of the anticipated scientific objectives.

16 Aug 2010

FDA approves ellaOne for emergency contraception

HRA Pharma announced today that the US Food and Drug Administration (FDA) granted approval for ella(R) (ulipristal acetate) as a prescription-only emergency contraceptive indicated for use within 120 hours (five days) of unprotected intercourse or a known or suspected contraceptive failure. ella is not intended for routine use as a contraceptive.

16 Aug 2010

Dyadic second-quarter 2010 total revenue decreases to $2.2 million

Dyadic International, Inc., a global biotechnology company focused on the discovery, development, manufacture and sale of specialty enzyme products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, today announced financial results for the second quarter ended June 30, 2010.

13 Aug 2010

PROFIT magazine ranks Prollenium as one of Canada's Fastest Growing Companies

Ario Khoshbin, President of Prollenium Medical Technologies Inc., a privately held specialty medical device company, reported today that his firm will continue to record strong year on year gains in revenues and profitability for its 2010 Fiscal Year ending June 30th. Over the past five years, Prollenium has recorded aggregate revenue growth of more than 524% ranking it amongst Canada's fastest growing firms.

13 Aug 2010

U.S. FDA purchases more licenses to Simulations Plus' DDDPlus software

Simulations Plus, Inc., a leading provider of software for pharmaceutical discovery and development, today announced that it has received a purchase order from the U.S. Food and Drug Administration to expand the number of licenses for the Company's DDDPlus™ simulation software.

13 Aug 2010

Soligenix’s net loss for second-quarter 2010 decreases to $1,577,000

Soligenix, Inc., a late-stage biopharmaceutical company, announced today its financial results for the second quarter of 2010.

13 Aug 2010

LabCorp announces collaboration between Esoterix Clinical Trials Services, Clearstone Central Laboratories

Laboratory Corporation of America Holdings announced today a collaboration between Esoterix Clinical Trials Services, a division of LabCorp, and Clearstone Central Laboratories, a global central laboratory specializing in drug development and pharmaceutical services.

13 Aug 2010

CeNeRx BioPharma raises $13 million through Series C financing to support TriRima Phase II trial

CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced completion of a $13 million Series C financing. Existing investors Perseus Soros Biopharmaceutical Fund, L Capital Partners and Pappas Ventures all participated in the financing. CeNeRx plans to use the proceeds to conduct a Phase II trial of its improved formulation of its novel antidepressant TriRima™.

13 Aug 2010

Catalyst second-quarter net loss decreases to $1,328,541

Catalyst Pharmaceutical Partners, Inc. today announced its financial results for the second quarter and six months ended June 30, 2010.

13 Aug 2010

Trubion Pharmaceuticals signs definitive merger agreement with Emergent BioSolutions

Trubion Pharmaceuticals, Inc. today announced the signing of a definitive merger agreement with Emergent BioSolutions Inc., in which Emergent has agreed to acquire Trubion. Under the terms of the agreement, each share of Trubion common stock will be converted into the right to receive an upfront payment of $1.365 per share in cash and 0.1641 shares of Emergent BioSolutions common stock.

13 Aug 2010

MDS Nordion extends cobalt-60 long-term supply agreement with Ontario Power Generation

MDS Nordion, a leading provider of products and services to the global health science market, today announced it has extended its existing agreement with Ontario Power Generation Inc., the Canadian-based electricity generation company, until 2020 for the secure supply of cobalt-60 used in gamma sterilization technologies around the world.

13 Aug 2010

Pharmaceuticals News and Research

Clinical trials activity of Synexus in Hungary increases 25% in first-half of 2010

R-Tech Ueno, Sucampo Pharmaceuticals request arbitration against Takeda Pharmaceutical

Watson to launch ella emergency contraceptive in fourth-quarter 2010

US WorldMeds announces acquisition of Solstice Neurosciences for $35M

Aeolus Pharmaceuticals second quarter 2010 net loss increases to $0.10 per share

Inovio Pharmaceuticals 2010 second quarter net loss decreases

Nymox second-quarter net loss increases to $1.75 million

Avenue to Access provides free prescription-size tube of ZITHRANOL-RR to stable plaque psoriasis patients

U.S. officials probing payments by drug and device makers to doctors overseas

AIBioTech receives new government contract worth $21 million

FDA approves ellaOne for emergency contraception

Dyadic second-quarter 2010 total revenue decreases to $2.2 million

PROFIT magazine ranks Prollenium as one of Canada's Fastest Growing Companies

U.S. FDA purchases more licenses to Simulations Plus' DDDPlus software

Soligenix’s net loss for second-quarter 2010 decreases to $1,577,000

LabCorp announces collaboration between Esoterix Clinical Trials Services, Clearstone Central Laboratories

CeNeRx BioPharma raises $13 million through Series C financing to support TriRima Phase II trial

Catalyst second-quarter net loss decreases to $1,328,541

Trubion Pharmaceuticals signs definitive merger agreement with Emergent BioSolutions

MDS Nordion extends cobalt-60 long-term supply agreement with Ontario Power Generation

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence